Cigna Expects Lower Growth in Popular GLP-1 Drug Prescriptions
Cigna beat second-quarter earnings and revenue estimates, raised its 2026 profit outlook and said GLP-1 utilization growth is moderating.
Cigna made more money than people expected and thinks it will do well next year, but fewer people are getting started on a popular weight-loss medicine than before. When a big health company sees a slowdown in one popular treatment, it's worth watching to see if that trend keeps going.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.